Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer

NCT03069950 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT03069950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03069950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
February 28, 2017
Completion date
May 16, 2019
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma metastatic to the liver